All News

Avanafil, an investigational phosphodiesterase type-5 inhibitor, appears to significantly improve erectile function with low rates of side effects, according to results from a randomized, placebo-controlled, phase III study.

Prostate cancer patients tend to opt for a major cancer center if they have severe disease, but stay closer to home for less complicated cases, even when offered a model of care that taps numerous experts, according to a study by researchers from Duke Cancer Institute, Durham, NC.

A scale used to measure bone metastases has been found useful in determining whether some prostate cancer patients are responding to chemotherapy, report researchers from Memorial Sloan-Kettering Cancer Center, New York.

New Jersey Governor Chris Christie has signed legislation opposing an October 2011 U.S. Preventive Services Task Force (USPSTF) draft recommendation that healthy men should no longer receive PSA tests as part of routine cancer screening.

The AUA recently honored Brigadier General (U.S. Army ret.) C. William Fox, Jr, MD, with honorary membership for outstanding service to his country and his profession.

Obesity appears to be associated with higher rates of prostate cancer screening across all races and ethnicities, recent study findings indicate.

Noise-canceling headphones playing a classical melody may reduce pain and anxiety in men undergoing a prostate biopsy, say researchers from Duke Cancer Institute, Durham, NC.

Veterans Affairs hospitals screen elderly men with limited life expectancies for prostate cancer at surprisingly high rates, even though guidelines recommend against such screening, according to a recent study.

Results from testing in an initial patient cohort indicate the potential for a six-gene, whole blood RNA-based expression panel to predict survival in men with progressive metastatic castration-resistant prostate cancer.

Post-radical prostatectomy erectile function recovery is much lower than physician-reported rates, a study indicates.

The advent of nerve-sparing radical prostatectomy and its outcomes has focused attention on the etiology of erectile dysfunction following all forms of prostate cancer intervention.

During periods of dramatic market fluctuation, it is important for investors to avoid emotional responses to investing.

There is a lot we can do to improve our practices' efficiency and productivity. One of the simplest methods is to decrease the no-show rate, a problem that affects most medical practices.

Peter R. Carroll, MD, MPH, discusses the positive and negative aspects of the U.S. Preventive Services Task Force prostate cancer screening recommendation and provides a unique perspective on how the urology community should respond.

Pain interference with daily functioning was significantly less in men with castrate-resistant prostate cancer who were treated with the RANK ligand inhibitor denosumab (XGEVA) compared to zoledronic acid (Zometa) as part of a multinational, double-blind, randomized trial.

Urologists and other physicians across the country now find themselves in the midst of a high stakes game of "chicken" on Capitol Hill, with their level of compensation for treating Medicare patients at stake.

Although percutaneous nephrolithotomy (PCNL) comprises only 4% to 6% of all stone surgeries, it behooves the urologist with an interest in stone disease to be facile in this treatment modality in order to offer patients the most appropriate and effective treatment for their stones.

A new AUA standard operating practice document aims to help with robotic surgery credentialing for practicing urologists and those in training.

Whether a coverage arrangement is in place makes all the difference when seeing another urologist's patients.

Results of in vitro studies indicate that E-twenty six (ETS) gene fusions in prostate cancer may be a biomarker of radiation resistance and a potential target for reversing radioresistance through treatment with a poly(ADP-ribose)polymerase 1 (PARP1) inhibitor.

A composite score calculated from a 46-gene RNA signature independently predicts cancer death among men with clinically localized prostate cancer managed by active surveillance.

Hiring a friend is usually not a good idea, because it can cause more problems in your practice than it solves.

Almost half of prostate cancer deaths occur among men with PSA levels in the top 10% when assessed at age 44 to 50 years. This small group could benefit from intense surveillance over the ensuing years, whereas in about half of men, three lifetime PSA tests appear sufficient to capture the risk of prostate cancer metastases or death 10 or more years in advance.

Among men treated with curative radiation therapy and neoadjuvant, adjuvant, or concurrent androgen deprivation therapy (ADT), about one-fourth fail to achieve or maintain true castrate levels of testosterone suppression.

Men with lower urinary tract symptoms (LUTS) associated with large prostates had significantly greater improvement in functional outcomes when treated with holmium laser enucleation of the prostate (HoLEP) than with photoselective vaporization of the prostate (PVP).

Surveys of patients and their partners have found previous numbers regarding post-op potency to be highly unrealistic, and results of recent studies, such as one from Memorial Sloan-Kettering Cancer Center, are closer to reality.

Researchers found that stretched penile length following radical prostatectomy for prostate cancer decreased until 36 months post-op, then at this point, the process appears to reach a nadir and reverse itself so that by 48 months, stretched length appeared to be fully restored at 5 years post-op.